Libivirumab
Libivirumab
Libivirumab (pronunciation: li-bi-vi-ru-mab) is a monoclonal antibody designed for the treatment of various cancer types.
Etymology
The name "Libivirumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-viru-" suggests its cancer-related use.
Function
Libivirumab works by binding to specific proteins on the surface of cancer cells, inhibiting their growth and proliferation. This is achieved through the activation of the body's immune system, which then targets and destroys the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Immune system: The body's defense against infectious organisms and other invaders.
Usage
Libivirumab is used in the treatment of various types of cancer, including breast cancer, lung cancer, and colorectal cancer. It is typically administered via intravenous infusion.
Side Effects
Like all medications, Libivirumab can cause side effects. Common side effects include fatigue, nausea, and fever. More serious side effects can include allergic reactions, heart problems, and immune system disorders.
External links
- Medical encyclopedia article on Libivirumab
- Wikipedia's article - Libivirumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski